317 related articles for article (PubMed ID: 33251185)
1. Supporting SARS-CoV-2 Papain-Like Protease Drug Discovery:
Ibrahim TM; Ismail MI; Bauer MR; Bekhit AA; Boeckler FM
Front Chem; 2020; 8():592289. PubMed ID: 33251185
[TBL] [Abstract][Full Text] [Related]
2. Facilitating SARS CoV-2 RNA-Dependent RNA polymerase (RdRp) drug discovery by the aid of HCV NS5B palm subdomain binders: In silico approaches and benchmarking.
Elghoneimy LK; Ismail MI; Boeckler FM; Azzazy HME; Ibrahim TM
Comput Biol Med; 2021 Jul; 134():104468. PubMed ID: 34015671
[TBL] [Abstract][Full Text] [Related]
3. Benchmarked molecular docking integrated molecular dynamics stability analysis for prediction of SARS-CoV-2 papain-like protease inhibition by olive secoiridoids.
Thangavel N; Albratty M
J King Saud Univ Sci; 2023 Jan; 35(1):102402. PubMed ID: 36338939
[TBL] [Abstract][Full Text] [Related]
4. Targeting multiple conformations of SARS-CoV2 Papain-Like Protease for drug repositioning: An in-silico study.
Ismail MI; Ragab HM; Bekhit AA; Ibrahim TM
Comput Biol Med; 2021 Apr; 131():104295. PubMed ID: 33662683
[TBL] [Abstract][Full Text] [Related]
5. Chemical-informatics approach to COVID-19 drug discovery: Monte Carlo based QSAR, virtual screening and molecular docking study of some
Amin SA; Ghosh K; Gayen S; Jha T
J Biomol Struct Dyn; 2021 Aug; 39(13):4764-4773. PubMed ID: 32568618
[TBL] [Abstract][Full Text] [Related]
6. Pharmacophore model-aided virtual screening combined with comparative molecular docking and molecular dynamics for identification of marine natural products as SARS-CoV-2 papain-like protease inhibitors.
Thangavel N; Albratty M
Arab J Chem; 2022 Dec; 15(12):104334. PubMed ID: 36246784
[TBL] [Abstract][Full Text] [Related]
7. Structure-Based Screening to Discover New Inhibitors for Papain-like Proteinase of SARS-CoV-2: An
Jamalan M; Barzegari E; Gholami-Borujeni F
J Proteome Res; 2021 Jan; 20(1):1015-1026. PubMed ID: 33350309
[TBL] [Abstract][Full Text] [Related]
8. Establishing an Analogue Based In Silico Pipeline in the Pursuit of Novel Inhibitory Scaffolds against the SARS Coronavirus 2 Papain-Like Protease.
Hajbabaie R; Harper MT; Rahman T
Molecules; 2021 Feb; 26(4):. PubMed ID: 33672721
[TBL] [Abstract][Full Text] [Related]
9. Microbial based natural compounds as potential inhibitors for SARS-CoV-2 Papain-like protease (PLpro): a molecular docking and dynamic simulation study.
Rahul S; Sarkar A
J Biomol Struct Dyn; 2022; 40(24):13848-13858. PubMed ID: 34730069
[TBL] [Abstract][Full Text] [Related]
10. Identifying structural-functional analogue of GRL0617, the only well-established inhibitor for papain-like protease (PLpro) of SARS-CoV2 from the pool of fungal metabolites using docking and molecular dynamics simulation.
Rao P; Patel R; Shukla A; Parmar P; Rawal RM; Saraf M; Goswami D
Mol Divers; 2022 Feb; 26(1):309-329. PubMed ID: 33825097
[TBL] [Abstract][Full Text] [Related]
11. In-silico docking studies of selected phytochemicals against papain like protease of SARS-Cov-2.
Saranya P; Karunya R; Keerthi Varshini G; Kowsikan K; Prathiksha R
Vegetos; 2023; 36(1):188-194. PubMed ID: 36530568
[TBL] [Abstract][Full Text] [Related]
12.
Hassan HHA; Ismail MI; Abourehab MAS; Boeckler FM; Ibrahim TM; Arafa RK
Molecules; 2023 Jan; 28(3):. PubMed ID: 36770963
[TBL] [Abstract][Full Text] [Related]
13. Promising antivirals for PLpro of SARS-CoV-2 using virtual screening, molecular docking, dynamics, and MMPBSA.
Kumari R; Kumar V; Dhankhar P; Dalal V
J Biomol Struct Dyn; 2023 Jul; 41(10):4650-4666. PubMed ID: 35510600
[TBL] [Abstract][Full Text] [Related]
14. Crystal structure of SARS-CoV-2 papain-like protease.
Gao X; Qin B; Chen P; Zhu K; Hou P; Wojdyla JA; Wang M; Cui S
Acta Pharm Sin B; 2021 Jan; 11(1):237-245. PubMed ID: 32895623
[TBL] [Abstract][Full Text] [Related]
15. Exploring naphthyl derivatives as SARS-CoV papain-like protease (PLpro) inhibitors and its implications in COVID-19 drug discovery.
Amin SA; Ghosh K; Singh S; Qureshi IA; Jha T; Gayen S
Mol Divers; 2022 Feb; 26(1):215-228. PubMed ID: 33675510
[TBL] [Abstract][Full Text] [Related]
16.
Huynh T; Cornell W; Luan B
Front Chem; 2020; 8():624163. PubMed ID: 33614597
[TBL] [Abstract][Full Text] [Related]
17. Large-Scale Virtual Screening for the Discovery of SARS-CoV-2 Papain-like Protease (PLpro) Non-covalent Inhibitors.
Garland O; Ton AT; Moradi S; Smith JR; Kovacic S; Ng K; Pandey M; Ban F; Lee J; Vuckovic M; Worrall LJ; Young RN; Pantophlet R; Strynadka NCJ; Cherkasov A
J Chem Inf Model; 2023 Apr; 63(7):2158-2169. PubMed ID: 36930801
[TBL] [Abstract][Full Text] [Related]
18. Identification of SARS-CoV-2 Papain-like Protease (PLpro) Inhibitors Using Combined Computational Approach.
Sencanski M; Perovic V; Milicevic J; Todorovic T; Prodanovic R; Veljkovic V; Paessler S; Glisic S
ChemistryOpen; 2022 Feb; 11(2):e202100248. PubMed ID: 35103413
[TBL] [Abstract][Full Text] [Related]
19. Identification of potent food constituents as SARS-CoV-2 papain-like protease modulators through advanced pharmacoinformatics approaches.
Bhowmick S; Saha A; AlFaris NA; ALTamimi JZ; ALOthman ZA; Aldayel TS; Wabaidur SM; Islam MA
J Mol Graph Model; 2022 Mar; 111():108113. PubMed ID: 34959151
[TBL] [Abstract][Full Text] [Related]
20. Chalcone-amide, a privileged backbone for the design and development of selective SARS-CoV/SARS-CoV-2 papain-like protease inhibitors.
Valipour M
Eur J Med Chem; 2022 Oct; 240():114572. PubMed ID: 35797899
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
